<VariationArchive VariationID="2412743" VariationName="NM_004380.3(CREBBP):c.4567_4568del (p.Phe1523fs)" VariationType="Deletion" Accession="VCV002412743" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2023-02-08" MostRecentSubmission="2023-02-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2401472" VariationID="2412743">
      <GeneList>
        <Gene Symbol="CREBBP" FullName="CREB binding protein" GeneID="1387" HGNC_ID="HGNC:2348" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3725054" stop="3880713" display_start="3725054" display_stop="3880713" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3775054" stop="3930120" display_start="3775054" display_stop="3930120" Strand="-" />
          </Location>
          <OMIM>600140</OMIM>
          <Haploinsufficiency last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_004380.3(CREBBP):c.4567_4568del (p.Phe1523fs)</Name>
      <CanonicalSPDI>NC_000016.10:3736195:AAAA:AA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3736196" stop="3736197" display_start="3736196" display_stop="3736197" variantLength="2" positionVCF="3736195" referenceAlleleVCF="GAA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3786197" stop="3786198" display_start="3786197" display_stop="3786198" variantLength="2" positionVCF="3786196" referenceAlleleVCF="GAA" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>NM_004380.3:c.4567_4568del</Name>
      </OtherNameList>
      <ProteinChange>F1485fs</ProteinChange>
      <ProteinChange>F1523fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.3736198_3736199del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.3736198_3736199del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.3786199_3786200del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.3786199_3786200del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009873.2" sequenceAccession="NG_009873" sequenceVersion="2" change="g.149517_149518del">
            <Expression>NG_009873.2:g.149517_149518del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079846.1" sequenceAccession="NM_001079846" sequenceVersion="1" change="c.4453_4454del">
            <Expression>NM_001079846.1:c.4453_4454del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073315.1" sequenceAccession="NP_001073315" sequenceVersion="1" change="p.Phe1485fs">
            <Expression>NP_001073315.1:p.Phe1485fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004380.3" sequenceAccession="NM_004380" sequenceVersion="3" change="c.4567_4568del" MANESelect="true">
            <Expression>NM_004380.3:c.4567_4568del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004371.2" sequenceAccession="NP_004371" sequenceVersion="2" change="p.Phe1523fs">
            <Expression>NP_004371.2:p.Phe1523fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1426" sequenceAccession="LRG_1426">
            <Expression>LRG_1426:g.149517_149518del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1426t1" sequenceAccession="LRG_1426t1">
            <Expression>LRG_1426t1:c.4567_4568del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1426p1" sequenceAccession="LRG_1426p1" change="p.Phe1523fs">
            <Expression>LRG_1426p1:p.Phe1523fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004380.3(CREBBP):c.4567_4568del (p.Phe1523fs) AND Rubinstein-Taybi syndrome due to CREBBP mutations" Accession="RCV002790011" Version="3">
        <ClassifiedConditionList TraitSetID="1898">
          <ClassifiedCondition DB="MedGen" ID="C4551859">Rubinstein-Taybi syndrome due to CREBBP mutations</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-01-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2023-02-07">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1898" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4360" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE</ElementValue>
                <XRef Type="Allelic variant" ID="600140.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600140.0005" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Broad thumbs and great toes, characteristic facies, and mental retardation</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to CREBBP mutations</ElementValue>
                <XRef ID="MONDO:0008393" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS1</ElementValue>
                <XRef Type="MIM" ID="180849" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CREBBP</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RTS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">CREBBP-Related Rubinstein-Taybi Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17534" />
                <XRef ID="17534" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353277" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C4551859" DB="MedGen" />
              <XRef ID="MONDO:0008393" DB="MONDO" />
              <XRef Type="MIM" ID="180849" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6450534" SubmissionDate="2023-01-27" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="48b3b685-f274-4618-a8ac-bef7f91c6260" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003761356" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The heterozygous p.Phe1523GlnfsTer5 variant in CREBBP was identified by our study in one individual with global developmental delay and agenesis of the corpus callosum. Trio exome analysis showed this variant to be de novo. The p.Phe1523GlnfsTer5 variant in CREBBP has not been previously reported in individuals with Rubinstein-Taybi syndrome 1. This variant was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein‚Äôs amino acid sequence beginning at position 1523 and leads to a premature termination codon 5 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the CREBBP gene is an established disease mechanism in Rubinstein-Taybi syndrome 1. In summary, this variant meets criteria to be classified as pathogenic for Rubinstein-Taybi syndrome 1. ACMG/AMP Criteria applied: PVS1, PS2_Supporting, PM2_Supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CREBBP" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_004380.3:c.4567_4568del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.10:g.3736198_3736199del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0008393" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12627697</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6450534" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0008393" MappingRef="MONDO">
        <MedGen CUI="C4551859" Name="Rubinstein-Taybi syndrome due to CREBBP mutations" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

